These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2871010)

  • 1. Low-dose treatment strategies.
    Van Putten T; Marder SR
    J Clin Psychiatry; 1986 May; 47 Suppl():12-6. PubMed ID: 2871010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome.
    Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
    J Clin Psychiatry; 1993 Feb; 54(2):59-62. PubMed ID: 8095259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for high-dose antipsychotics.
    Brotman AW; McCormick S
    J Clin Psychiatry; 1990 Apr; 51(4):164-6. PubMed ID: 1969862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.
    Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
    Isr J Psychiatry Relat Sci; 1995; 32(4):268-75. PubMed ID: 8641856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.
    Kane JM; Woerner M; Sarantakos S
    J Clin Psychiatry; 1986 May; 47 Suppl():30-3. PubMed ID: 2871014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
    Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.